Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial

@article{vanGelder2008ComparingMM,
  title={Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial},
  author={Teun van Gelder and Helio Tedesco Silva and Johan W. de Fijter and Klemens Budde and D. M. Kuypers and Gunnar Tyd{\'e}n and Aleksander L{\~o}hmus and Claudia Sommerer and Anders Hartmann and Yannick Le Meur and Michael Oellerich and D Holt and Burkhard T{\"o}nshoff and Paul A. Keown and Scott B. Campbell and Richard D. Mamelok},
  journal={Transplantation},
  year={2008},
  volume={86},
  pages={1043-1051}
}
Background. Fixed-dose mycophenolate mofetil (MMF) reduces the incidence of acute rejection after solid organ transplantation. The Fixed-Dose Concentration Controlled trial assessed the feasibility and potential benefit of therapeutic drug monitoring in patients receiving MMF after de novo renal transplant. Methods. Patients were randomized to a concentration-controlled (n=452; target exposure 45 mg hr/L) or a fixed-dose (n=449) MMF-containing regimen. The primary endpoint was treatment failure… 
Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study
TLDR
Mycophenolate mofetil at intensified and individually adjusted dose in combination with Tac in de novo liver transplant recipients allows CS discontinuation from day 1 posttransplant with good tolerance and very low rejection incidence.
Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients
TLDR
The initially intensified EC-MPS dosing regimen was associated with higher MPA exposure, significantly lower rate of BPAR, and comparable safety, however, the intensified regimen did not affect graft function or survival.
Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function
TLDR
The initial MMF dose has implications for the incidence of leukopaenia and rejection and clinical equipoise remains regarding the optimal initial mycophenolate dose in tacrolimus-treated renal transplant recipients.
Tolerability of mycophenolate sodium in renal transplant recipients
TLDR
In this cohort, changes in the dose of mycophenolate were associated with increased risk of acute rejection and permanent discontinuation was associated with inferior patient and graft survival.
Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial
TLDR
In the APOMYGRE trial, therapeutic MPA monitoring using a limited sampling strategy reduced the risk of treatment failure and acute rejection in renal allograft recipients during the first 12 months posttransplantation, at neutral cost.
The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.
TLDR
A limited intensified dose of MMF increased early MPA exposure and was well tolerated and resulted in a trend for fewer treated acute rejections at 6 months.
Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial.
  • B. HöckerT. van Gelder B. Tönshoff
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2011
TLDR
The overall efficacy and tolerability of MMF appear to be comparable between paediatric and adult patients, and further studies are needed to validate these results.
Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.
  • P. JacobsonJiayin Huang D. Weisdorf
  • Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2010
Relationship of Tacrolimus Exposure and Mycophenolate Mofetil Dose With Renal Function After Renal Transplantation
TLDR
Tacrolimus seems to have a moderate but consistent nephrotoxic effect even in modern efficient immunosuppressive regimens where it is used at lower doses than in previous years.
Early Steroid Withdrawal and Optimization of Mycophenolic Acid Exposure in Kidney Transplant Recipients Receiving Mycophenolate Mofetil
TLDR
In low-immunological risk kidney recipients, MMF combined with CsA allows early corticosteroid discontinuation with good tolerability and in this group of patients, TDM of MMF does not improve clinical outcome.
...
...

References

SHOWING 1-10 OF 23 REFERENCES
Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation
  • Y. Le MeurM. Büchler P. Marquet
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2007
TLDR
Therapeutic MPA monitoring using a limited sampling strategy can reduce the risk of treatment failure and acute rejection in renal allograft recipients 12 months posttransplant with no increase in adverse events.
Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
TLDR
It is concluded that a systematic graft biopsy and a pharmacokinetic study of mycophenolic acid are needed to reduce the risk for acute rejection after CsA withdrawal.
The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation
TLDR
More data are needed to fully establish the meaning of the reported prognostic value of preoperative inosine monophosphate dehydrogenase (IMPDH) activity, and longitudinal studies monitoring IMPDH activity after transplantation are eagerly awaited.
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
TLDR
MPA Cpredose and MPA AUC are significantly related to the incidence of biopsy-proven rejection after kidney transplantation, whereas MMF dose is significantly relatedto the occurrence of adverse events.
The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.
TLDR
Investigation of the pharmacokinetic (PK)/pharmacodynamic relationship of total and free MPA and PK values for the assessment of an individual's MPA PK parameters indicates that therapeutic drug monitoring of MPA has the potential for optimization of MMF efficacy in this patient population by steering patients away from the low values of M PA PK variables that are associated with an increased rejection risk.
Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation
TLDR
A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide immunosuppression with mycophenolate mofetil was held in New York in December 2004, and it was agreed that TDM might help optimize outcomes, especially in patients at higher risk of rejection.
Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.
TLDR
Exposure to total MPA, as determined by MPA clearance, significantly increased with increasing renal function, albumin level, and hemoglobin as well as decreasing cyclosporine predose level, which provides an indication for therapeutic drug monitoring as MPA exposure may be altered.
Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
TLDR
The development of monitoring strategies for this drug appears to be promising, with the ability of predose levels or AUC(0-12h) to discriminate between cases with no complications and those with acute rejection, adverse events, or gastrointestinal disorders observed during the early posttransplant course confirmed.
Clinical Application of Population Pharmacokinetic Methods Developed for Immunosuppressive Drugs
TLDR
The feasibility of accurate dose adjustment using these maximum a posteriori Bayesian estimators is shown through preliminary results from 2 ongoing multicenter clinical trials, 1 evaluating an AUC-controlled cyclosporine-sparing strategy in stable renal transplants, the second evaluating the benefit of MMF therapeutic drug monitoring based on MPA AUC0-12h in de novo renal transplant recipients.
Predicting the Usefulness of Therapeutic Drug Monitoring of Mycophenolic Acid: A Computer Simulation
TLDR
To reach target AUC levels as soon as possible in this cyclosporine-treated population, it appears that larger MMF doses as currently recommended are necessary in the first month after transplantation.
...
...